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Abstract Vitamin D has attracted considerable interest in re-
cent years, with a marked increase in diagnosis of vitamin D
deficiency seen among children in clinical practice in the UK.
The economic implications of this change in diagnostic be-
haviour have not been explored. We performed a cohort study
to examine longitudinal trends in healthcare expenditure aris-
ing from vitamin D testing and prescribing for children in
primary care in England, using the electronic healthcare re-
cords of 722,525 children aged 0–17 years held in The Health
Improvement Network database. Combined costs of vitamin
D tests and prescriptions increased from £1647 per 100,000
person-years in 2008 (95% CI, £934 to £3007) to £28,913 per
100,000 person-years in 2014 (95% CI, £26,361 to £31,739).
The total cost of vitamin D prescriptions and tests for children
in primary care at the national level in England in 2014 was
estimated to be £4.31 million (95% CI, £2.96–£6.48 million).
Conclusion: There has been a marked increase in
healthcare expenditure on vitamin D tests and prescriptions
for children in primary care over the past decade. Future re-
search should explore the drivers for this change in diagnostic
behaviour and the reasons prompting investigation of vitamin
D status in clinical practice.
What is Known:
• Vitamin D deficiency has attracted considerable interest in recent years,
with a marked increase in diagnosis seen in children.
• The economic implications of this change in diagnostic behaviour have
not been explored.
What is New:
• There has been a large increase in healthcare expenditure on vitamin D
tests and prescriptions for children in primary care in England over the
past decade (> 15 fold between 2008 and 2013).
• Screening of vitamin D status in children without specific risk factors or
clinical features of deficiency may represent avoidable healthcare
expenditure.
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Introduction
Vitamin D has attracted considerable interest in recent years.
Alongside concerns regarding a rise in cases of rickets among
children in developed countries [1], a large body of observa-
tional research has stimulated debate regarding the postulated
role of vitamin D deficiency (VDD) in numerous other dis-
eases (beyond the hormone’s established functions in bone
metabolism and calcium homeostasis) [15].
As vitamin D has attracted increasing attention, large in-
creases in testing have been reported in adult practice in
Australia and Canada [3]. Given the controversy regarding
threshold 25-hydroxyvitamin D (25-OH-D) values used to
define deficiency [7, 9, 14, 15], the high prevalence of low
25-OH-D levels in the general population, and uncertainty
regarding whether treatment of biochemical VDD in asymp-
tomatic individuals improves health outcomes, some authors
have suggested that the large growth in testing in recent years
reflects potential over-diagnosis and unnecessary health care
costs [3, 15]. In UK children, there has been a marked increase
in diagnosis of VDD in clinical practice over the last decade
[2]. The aim of this study was to explore the economic impli-
cations of this change in diagnostic behaviour. Using a large
population-based cohort of children in England, we examined
longitudinal trends in healthcare expenditure arising from vi-
tamin D testing and prescribing in primary care.
Methods
A cohort study was performed using The Health Improvement
Network (THIN) database, which contains anonymised elec-
tronic health records of patients registered with 639 participat-
ing UK general practices (www.epic-uk.org). A subset of
THIN practices in England (n = 156) linked to patient-level
Hospital Episode Statistics (HES) data (http://content.digital.
nhs.uk/hes) were included, tomaximise information regarding
ethnicity.
Children aged 0–17 years, actively registered with a partic-
ipating practice at any point between 2000 and 2014, were
included. Children with chronic renal disease, liver disease,
or conditions associated with gastrointestinal malabsorption
were excluded (n = 3918, 0.5% of the cohort). Individuals
were followed up from the latest of their date of practice reg-
istration, the date the practice met two pre-defined quality
indicators for electronic data recording (acceptable mortality
recording and acceptable computer usage) [10], or 1st January
2000. Exit from follow-up was the earliest of the date of trans-
fer out of practice, the date the practice stopped contributing
data to THIN, the mid-point of the 18th year after birth, date of
death, or 31st December 2014.
Ethnicity was grouped into the 2001 UK Census 5-
category classification, and was assigned from THIN where
available, and supplemented with HES data [11]. For individ-
uals with multiple ethnicity categories recorded (0.3% of the
cohort), the most frequently recorded category was used. For
children with missing ethnicity, maternal ethnicity was taken
as a proxy measure, using methods described elsewhere [2].
The primary outcome was the total cost of 25-OH-D tests
and prescriptions for pure preparations of calciferol
(colecalciferol or ergocalciferol) in the study cohort.
Prescriptions for multivitamin preparations and activated
forms of vitamin D (calitriol and alfacalcidol) were excluded,
as they are not indicated in the treatment of primary VDD. The
unit cost of a 25-OH-D test was taken as £15, based on data
from several NHS trusts. Unit costs of different calciferol
preparations were derived from Prescription Cost Analysis
(PCA) for England 2014, using the net ingredient cost per
quantity of drug (NIC_Qty) [8]. Where there were multiple
drugs with identical formulation and strength listed in the
PCA, a weighted mean unit price was calculated using the
relative frequency (N) with which each drug (i) was dis-
pensed:
Weighted unit price ¼
∑
i
NIC Qtyi  Nið Þ
∑
i
N i
Prescription costs were calculated by multiplying the
weighted unit price by the quantity prescribed. Mean prescrip-
tion costs were calculated for each year between 2000 and
2014, using bootstrapping to derive confidence intervals due
to skewed data. Total costs of prescriptions and tests in each
year were calculated by multiplying mean unit costs by rates
of prescription and testing in the cohort. Multivariable Poisson
regression models examined differences in rates of prescrip-
tion and testing by ethnicity, age group, sex, urban or rural
area of residence, and season, with inclusion of the general
practice as a random effect to account for data clustering.
National costs for 2014 were estimated using the direct
standardisation method. Observed costs in the cohort (per
100,000 person-years) in 2014 were stratified by age, sex,
and ethnicity and applied to mid-2014 population estimates
for England (www.ons.gov.uk). Analyses were performed
using Stata 14.2 (StataCorp LP).
Results
The study cohort consisted of 722,525 children from 156
practices in England, with a median follow-up time of
3.9 years (interquartile range 1.5–8.1). Descriptive character-
istics are shown in Table 1.
There was a marked increase in healthcare costs arising
from both vitamin D tests and prescriptions in primary care
after 2008 (Fig. 1 and Supplementary Table 1). Combined
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costs of calciferol prescriptions and 25-OH-D tests increased
from £1647 per 100,000 person-years in 2008 (95% CI,
£934–£3007) to £28,913 per 100,000 person-years in 2014
(95% CI, £26,361–£31,739). Rates of vitamin D testing and
prescription were higher in older children, girls, and children
from ethnic minority backgrounds (Supplementary Table 2).
Rates of testing and prescription were marginally higher in
spring compared to other seasons, and did not differ signifi-
cantly by urban or rural area of residence.
Liquid formulations of calciferol accounted for 35% of pre-
scriptions, and 76% of prescription costs. The majority of calcif-
erolprescriptions(70%,accountingfor75%ofprescriptioncosts)
were for doses higher than those recommended for prophylactic
supplementation or maintenance therapy (> 1000 units/day).
Applying stratified cost rates (by age, sex, and ethnicity) to
national population estimates, the total cost of vitamin D pre-
scriptions and tests for children in primary care in England in
2014 was estimated to be £4.31 million (95% CI, £2.96–£6.48
million), of which the cost of calciferol prescriptions was £2.62
million (95%CI, £1.65–£4.24million) and the cost of 25-OH-D
tests was £1.69million (95%CI, £1.31–£2.24million).
Discussion
Using a large representative sample of English children, we
observed a marked increase (> 15-fold) in healthcare expendi-
ture on vitamin D tests and prescriptions in primary care be-
tween2008and2013.Thismirrors trendsseen inadult practice;
expenditure on 25-OH-D tests in Australia is reported to have
increased from 1 to 95.6 million Australian dollars between
2000 and 2010, and from 38 to 150 million Canadian dollars
between 2009 and 2012 in the Ontario province of Canada [3].
THIN data is prospectively collected, and representative of
real-life clinical practice. The cohort has been shown to be
broadly representative of the UK general population [4].
Prescriptions and test results are particularly well recorded in
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Fig. 1 Time trends in costs
arising from vitamin D
prescriptions and tests in children
in primary care, 2000 to 2014.
(Costs of vitamin D prescriptions
and tests are shown separately
(red and green lines) as well as
combined (blue line), dashed
lines indicate 95% confidence
intervals)
Table 1 Descriptive characteristics of the study cohort (N = 722,525)
Characteristic Value
Age at entry to follow-up in years, median (IQR) 3.9 (0.15 to 10.5)
Sex, n (%)
Male 371,835 (51.5)
Female 350,690 (48.5)
Ethnicity, n (%)a
White 499,132 (69.1)
Asian or Asian British 35,322 (4.9)
Black or Black British 25,315 (3.5)
Mixed 15,886 (2.2)
Chinese or other ethnic group 13,712 (1.9)
Missing 133,158 (18.4)
Area of residence, n (%)
Urban 568,232 (78.7)
Rural 123,134 (17.0)
Missing 31,159 (4.3)
IQR interquartile range
a Ethnicity data was available from the child’s THIN or Hospital Episode
Statistics record for 67.6% of the cohort, and maternal ethnicity was
available as a proxy measure for 14.0%
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electronic health data, due to computerised prescribing and
electronic linkage with laboratory services. However, the
study is limited to primary care and does not capture costs of
testing and prescribing in secondary care. Furthermore, reli-
able resource use data was not available for consultations or
hospital admissions, as it was not known whether episodes
were primarily related to VDD or other clinical issues. Thus,
although the results do not represent total healthcare costs
associatedwith VDDdiagnosis and treatment in children, they
do indicate a clear trend for increasing costs over the last
decade. It was not possible to investigate whether vitamin D
testing and prescribing was associated with children’s body
mass index, as this variable is not well recorded in THIN.
Biochemical VDD has a high prevalence in the general popu-
lation, and testing is likely to identify a significant proportion of
abnormal results in anypatientgroup[15].However, thechoiceof
threshold 25-OH-D levels used to define deficiency varies across
guidelines internationally and has a limited evidence base in chil-
dren [7, 14, 15]. Whilst the benefits of treatment with pharmaco-
logical doses of vitaminD are clear in childrenwith symptomatic
deficiency, there is no evidence that testing and treating asymp-
tomatic individuals results in improved health outcomes com-
pared to prophylaxis with low-dose supplements [15]. For these
reasons, the UK Institute for Health and Care Excellence (NICE)
[13], US Endocrine Society [9], European Society for Paediatric
Endocrinology [12], andEuropeanAcademyofPaediatrics [7] all
adviseagainst the routine screeningofvitaminDstatus.However,
they recommend a strategy of primary prevention of deficiency
through universal low-dose vitamin D supplementation for all
young children and pregnant women. It has been suggested that
theprimaryreasons for requesting25-OH-Dmeasurement inchil-
dren should relate to symptoms of rickets/osteomalacia ormuscle
weakness,biochemicalorradiologicalevidenceofmetabolicbone
disease, hypocalcaemia, or the presence of disorders that interfere
with vitaminDmetabolism or absorption [15]. Testing outside of
this context requires careful consideration of whether VDD is
related to the child’s presentation or is a coincidental finding.
Evidence that vitamin D has a clinically relevant role in the
aetiology of non-musculoskeletal health outcomes is limited [7,
15].
The data available did not permit exploration of how much
the increase in testing and treatment in children is being driven
by improved recognition of symptomaticVDD, or by testing in
other clinical situations (for example, screening of asymptom-
atic children, or testing prompted by the presence of non-
musculoskeletal diseases that have been linked to VDD such
as diabetes, atopic disorders, and infectious diseases).
However,adultdatasuggests that themajorityofvitaminDtests
areperformed inindividualswithoutspecificclinical featuresor
risk factors for deficiency; the introduction of a defined set of
clinical criteriapermitting25-OH-D testing inAlberta,Canada,
in 2015 resulted in a 92% reduction in the number of tests or-
dered, and annual cost savings of almost 4 million US dollars
[6]. A large reduction in healthcare expenditure on vitamin D
testshas alsobeenobserved inAustralia following the introduc-
tion of a policy for targeted testing [5].
In summary, there has been a large increase in healthcare
expenditure on vitamin D tests and prescriptions for children
in primary care over the past decade. Screening of vitamin D
levels in children without specific risk factors or clinical fea-
tures of deficiency may represent avoidable healthcare expen-
diture, and resources may be better used if directed towards
improving the uptake of inexpensive multivitamin supple-
ments by population groups at high-risk of deficiency.
Future studies should explore the reasons for investigation of
vitamin D status in children in clinical practice.
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